- Klíčová slova
- studie GETUG 16,
- MeSH
- analýza přežití MeSH
- antagonisté androgenů farmakologie terapeutické užití MeSH
- lidé MeSH
- nádory prostaty * farmakoterapie radioterapie MeSH
- protinádorové látky farmakologie terapeutické užití MeSH
- protokoly protinádorové léčby MeSH
- radioterapie využití MeSH
- randomizované kontrolované studie jako téma MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
Comorbidities may increase the negative effects of specific anticancer treatments such as androgen suppression therapy (AST). OBJECTIVES: To compare 6 months of AST and radiation therapy (RT) to RT alone and to assess the interaction between level of comorbidity and all-cause mortality. DESIGN, SETTING, AND PATIENTS: At academic and community-based medical centers in Massachusetts, between December 1, 1995, and April 15, 2001, 206 men with localized but unfavorable-risk prostate cancer were randomized to receive RT alone or RT and AST combined. All-cause mortality estimates stratified by randomized treatment group and further stratified in a postrandomization analysis by the Adult Comorbidity Evaluation 27 comorbidity score were compared using a log-rank test. MAIN OUTCOME MEASURE: Time to all-cause mortality. RESULTS: As of January 15, 2007, with a median follow-up of 7.6 (range, 0.5-11.0) years, 74 deaths have occurred. A significant increase in the risk of all-cause mortality (44 vs 30 deaths; hazard ratio [HR], 1.8; 95% confidence interval [CI], 1.1-2.9; P = .01) was observed in men randomized to RT compared with RT and AST. However, the increased risk in all-cause mortality appeared to apply only to men randomized to RT with no or minimal comorbidity (31 vs 11 deaths; HR, 4.2; 95% CI, 2.1-8.5; P < .001). Among men with moderate or severe comorbidity, those randomized to RT alone vs RT and AST did not have an increased risk of all-cause mortality (13 vs 19 deaths; HR, 0.54; 95% CI, 0.27-1.10; P = .08). CONCLUSIONS: The addition of 6 months of AST to RT resulted in increased overall survival in men with localized but unfavorable-risk prostate cancer. This result may pertain only to men without moderate or severe comorbidity, but this requires further assessment in a clinical trial specifically designed to assess this interaction. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00116220.
- MeSH
- adenokarcinom farmakoterapie radioterapie MeSH
- adjuvantní chemoterapie MeSH
- antagonisté androgenů terapeutické užití MeSH
- flutamid terapeutické užití MeSH
- hormon uvolňující gonadotropiny agonisté MeSH
- hormonální protinádorové látky terapeutické užití MeSH
- Kaplanův-Meierův odhad MeSH
- komorbidita MeSH
- konformní radioterapie MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádory prostaty farmakoterapie mortalita radioterapie MeSH
- následné studie MeSH
- příčina smrti MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
AUA update series, ISSN 1213-1636 lekce 5, 2003
8 stran : ilustrace, tabulka ; 30 cm
- MeSH
- adenokarcinom MeSH
- nádory prostaty MeSH
- prostatektomie MeSH
- prostatický specifický antigen MeSH
- Konspekt
- Patologie. Klinická medicína
- NLK Obory
- onkologie
- urologie
- NLK Publikační typ
- brožury